Unimpressed With Company, Ibex Says 'No' To Miraculins' Unsolicited Acquisition Offer | GenomeWeb
We’re just not that into you.
 
That’s the gist of the response Ibex gave to Miraculins after it announced late last week that it intends to make an unsolicited bid to acquire Ibex.
 
In a press release disclosing Miraculins’ offer, President Jim Charlton said that “the cancer diagnostic programs of Miraculins and Ibex are extremely complementary, and future opportunities for our companies are enhanced by this transaction.” 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.